Johnson & Johnson (JNJB34.SA)
| Previous close | 50.25 |
| Open | 50.25 |
| Bid | 50.34 x 0 |
| Ask | 50.40 x 0 |
| Day's range | 50.16 - 50.40 |
| 52-week range | 47.60 - 58.25 |
| Volume | |
| Avg. volume | 15,984 |
| Market cap | 1.818T |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 22.09 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.74 (3.46%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
Shockwave Medical Reports First Quarter 2024 Financial Results
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. “The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of ou
- Business Wire
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual "Prepackaged" Reorganization
NEW BRUNSWICK, N.J., May 01, 2024--Johnson & Johnson (NYSE: JNJ) (the "Company") today announced a proposed Plan of Reorganization (the "Plan") by its subsidiary, LLT Management LLC ("LLT"), for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against it and its affiliates in the United States.
- Business Wire
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
NEW BRUNSWICK, N.J., April 16, 2024--In the section titled "Full-Year 2024 Guidance", in the table, row titled "Operational Sales2,5/ Mid-point", the numbers for the April 2024 column should read: $88.7B – $89.1B / $88.9B (instead of: $88.7B – $89.1B / $88.0B).
